A 1.2mg once-daily injection of Victoza, also known as liraglutide, is a clinically and cost effective option when used with two oral anti-diabetic pills for obese patients with type 2 diabetes, the National Institute of Clinical Excellence (NICE) said.
Liraglutide is part of a new class of a group of new diabetes drugs that reduce glucose levels by stimulating the release of insulin only when glucose levels become too high. The drug also suppresses appetite.
NICE has asked for more information to support the wider use of the drug when given with only one anti-diabetic tablet.
Manufacturer Novo Nordisk said it was encouraged by the preliminary NICE findings and must now await final guidance from the body in June.
Liraglutide has been available in Britain since last July but the positive recommendation from NICE means it will now be used on the NHS.
Copyright Press Association 2010
The National Institute for Clinical Excellence